Px HealthCare (Px) has developed the only validated, personalised medical support platform for cancer patients, called OWise, which has been demonstrated to improve the patient – physician relationship . Originally developed in the Netherlands, the award-winning mobile app ‘OWise breast cancer’ has been independently studied, revealing that 90% of the patients and 90% of the treating clinicians recommend OWise to breast cancer patients. With the widespread use of smartphones, OWise is designed to support patients as part of their everyday life during treatment. Recently, NHS England has selected OWise to be part of its Innovation Accelerator.
The OWise platform comprises a large-scale database of anonymised patient reported outcome data, which is used to improve clinical outcomes in cancer. Px applies advanced data-analytics to obtain sought-after insights into the “patient reported outcomes” of cancer treatments. Near-term revenues have been planned from the licensing of Own Labe...
Px HealthCare (Px) has developed the only validated, personalised medical support platform for cancer patients, called OWise, which has been demonstrated to improve the patient – physician relationship . Originally developed in the Netherlands, the award-winning mobile app ‘OWise breast cancer’ has been independently studied, revealing that 90% of the patients and 90% of the treating clinicians recommend OWise to breast cancer patients. With the widespread use of smartphones, OWise is designed to support patients as part of their everyday life during treatment. Recently, NHS England has selected OWise to be part of its Innovation Accelerator.
The OWise platform comprises a large-scale database of anonymised patient reported outcome data, which is used to improve clinical outcomes in cancer. Px applies advanced data-analytics to obtain sought-after insights into the “patient reported outcomes” of cancer treatments. Near-term revenues have been planned from the licensing of Own Label versions of OWise to patient organisations and cancer clinics, resulting in income while expanding the user data collection. In the medium term, Px aims to commercialise licences to the acquired insights and intellectual property to health care payers and pharmaceutical companies. As OWise is prescribed by physicians, it is the first oncology platform that can connect patients, physicians and payers with the clear potential to benefit all three groups.
Px was established by serial, life sciences entrepreneur, Dr. Anne Bruinvels, who previously founded Curidium, a data-mining biotechnology company, which she led from inception to a listing on the AIM of the London Stock Exchange.
More information

Investors

FICHe
Admin
FICHe Follow the Future Internet CHallenge eHealth!